News

Public · Published

Barclays maintains Stryker at Overweight, lowers price target to $365 from $375

Barclays kept an Overweight rating on Stryker but lowered its price target to $365 from $375, a 2.7% decrease. The new target implies 17.1% upside from the October 29 close of $311.75. Other recent targets ranged from $300 to $390.

Published:

Updated:

What happened

Barclays kept an Overweight rating on Stryker but lowered its price target to $365 from $375, a 2.7% decrease. The new target implies 17.1% upside from the October 29 close of $311.75. Other recent targets ranged from $300 to $390.

Confirmed

Global impact / market context

A lower price target still above the current share price signals Barclays expects gains but has trimmed its expected upside, which means investors receive a mildly less optimistic reference point. That can shape how buyers judge whether Stryker's current price already reflects much of the expected growth.

Analyst inference

Other analysts publishing recent notes on Stryker hold ratings from Hold to Buy, with price targets spread between $300 and $390. That wide range shows divided views on how much the medical technology company is worth, so Barclays' small cut fits within an already mixed analyst picture.

Analyst inference

What to watch

  1. Barclays' $365 target sits near the middle of the recent $300 to $390 range, so watch whether other analysts move their targets closer to it. Confirmed
  2. Watch for future Stryker analyst notes to see whether the rating stays Overweight or shifts, since a rating change would alter the expected direction. Proposed
  3. Track Stryker's reported revenue and costs, because weaker profit per sale could prompt more price target cuts like Barclays' modest reduction. Analyst inference

Evidence

  • Original source link unavailable